EP
ZYME icon

Eudaimonia Partners’s Zymeworks ZYME Stock Holding History

Eudaimonia Partners’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-500
Closed -$16K – 1408
2021
Q1 		$16K Hold
500
– – ﹤0.01% 1033
2020
Q4 		$24K Hold
500
– – 0.01% 816
2020
Q3 		$23K Buy
+500
New +$17.2K 0.01% 766

Other funds holding ZYME

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Eudaimonia Partners's ZYME Position: Q2 2021 in Review

Eudaimonia Partners sold out of Zymeworks (ZYME) in Q2 2021, closing a stake of 500 shares — an estimated $16K sold.

Eudaimonia Partners first reported a position in ZYME in Q3 2020 and held it in 3 quarters. The position peaked at $24K in Q4 2020. 109 funds tracked by Wall St. Rank hold ZYME as of Q2 2021.

  • Eudaimonia Partners reported no remaining Zymeworks position as of Q2 2021 after selling out during the quarter.
  • Eudaimonia Partners sold 500 Zymeworks shares in Q2 2021, an estimated $16K.
  • Eudaimonia Partners first reported a position in Zymeworks in Q3 2020 and held it in 3 quarters.
  • Eudaimonia Partners's Zymeworks position peaked at $24K in Q4 2020.
  • 109 funds tracked by Wall St. Rank held Zymeworks as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.